Ensysce Biosciences receives U.S. patent for OUD treatment

Ensysce Biosciences (ENSC) received a Notice of Allowance from the U.S. Patent and Trademark Office for the issuance of a patent entitled: Enzyme-Cleavable Methadone Prodrugs and Methods of Use Thereof including both composition of matter and method of use claims. PF9001, the innovative medication covered by this patent, is designed to provide a safer treatment option for opioid use disorder by using Ensysce’s TAAP and MPAR abuse deterrent and overdose protection technologies. Methadone has long been a cornerstone treatment for OUD, but its use has been limited by concerns over cardiac side effects, respiratory depression, and risk of overdose. Ensysce has developed a new class of agents for the treatment for OUD in the form of PF9001. This new drug is a significant advancement in the treatment of OUD, with data demonstrating a reduction in potential for cardiotoxicity, validating MPAR overdose protection, and indications of potentially delivering a prolonged and predictable effect following once daily dosing.